Protein tyrosine phosphatases such as PTPN6 can be downregulated in various neoplasms. PTPN6 expression by immunohistochemistry in 40 diffuse large B-cell lymphoma (DLBCL) tumors was lost or suppressed in 53% (21/40). To elucidate the molecular mechanisms of PTPN6 suppression, we performed a comprehensive epigenetic analysis of PTPN6 promoter 2 (P2). None of the DLBCL primary tumors (0/37) had PTPN6 hypermethylation on the CpG1 island using methylation-specific PCR, pyrosequencing, and high-resolution melting assays. However, hypermethylation in 57% (21/37) of cases was found in a novel CpG island (CpG2) in P2. PTPN6 gene suppression was reversed by 5-aza-deoxycytidine (5-Aza), a DNA methyltransferase inhibitor, and the histone deacetylase inhibitor (HDACi) LBH589. LBH589 and 5-Aza in combination inhibited DLBCL survival and PTPN6 hypermethylation at CpG2. The role of histone modifications was investigated with a chromatin-immunoprecipitation assay demonstrating that PTPN6 P2 is associated with silencing histone marks H3K27me3 and H3K9me3 in DLBCL cells but not normal B cells. 3-Deazaneplanocin A, a histone methyltransferase inhibitor, decreased the H3K27me3 mark, whereas HDACi LBH589 increased the H3K9Ac mark within P2 resulting in re-expression of PTPN6. These studies have uncovered novel epigenetic mechanisms of PTPN6 suppression and suggest that PTPN6 may be a potential target of epigenetic therapy in DLBCL.
INTRODUCTION
The standard chemo-immunotherapy treatment of diffuse large B-cell lymphoma (DLBCL) 1, 2 cures approximately 60% of patients; new approaches are needed to improve the outcome for the other 40%. 3 In designing these new treatments, it is vital to identify novel tumor targets that will enable clinicians to individualize therapy based on tumor signal pathway activation profiles. DLBCL is characterized by overexpression of several signaling pathways such as nuclear factor-kB and Janus kinase 2/ Signal transducer and activator of transcription 3 (JAK2/STAT3) (ref. [4] [5] [6] [7] because of various mechanisms such as genetic mutations or through cytokine deregulation. In addition, other mechanisms, such as epigenetic silencing of protein tyrosine phosphatases such as protein tyrosine phosphatase 6 (PTPN6, also known as SHP1), may also contribute to various pathway deregulation.
8 PTPN6 acts as a negative regulator of several signal transduction pathways by dephosphorylating the receptor-associated kinases such as Src and JAK/STAT family kinases. 9, 10 Loss of PTPN6 contributes to JAK3/STAT3 activation in ALK þ anaplastic large T-cell lymphomas. 11 Deregulation of these pathways such as STAT3 and Src can promote cell growth leading to tumor development of various kinds of tumors.
The PTPN6 gene in humans is encoded by 17 exons and has two Src homology 2 domains, which are required for binding to phosphorylated tyrosine residues. 12 The PTPN6 gene also has two promoter regions that are 7 kb apart. The longer region (PTPN6 1A or P1) is expressed primarily in non-hematopoietic cells, whereas the shorter region (PTPN6 1B or P2) is expressed only in cells of hematopoietic lineage. [12] [13] [14] PTPN6 expression driven by P1 in nonhematopoietic cell such as epithelial or neuronal cells is low compared with the expression regulated by P2 in hematopoietic cells. 12, 15 Decreased expression of PTPN6 because of DNA hypermethylation of CpG island in the PTPN6 P2 promoter has been reported in various hematological malignancies. [16] [17] [18] [19] The aims of these studies were focused on whether PTPN6 was lost in DLBCL primary samples and cell lines, understanding the role of various epigenetic mechanisms including CpG hypermethylation and histone modifications in PTPN6 loss, and whether PTPN6 in DLBCL can be re-expressed with epigenetic therapy.
MATERIAL AND METHODS

Patient samples and cell lines
Tissue from formalin-fixed paraffin-embedded (FFPE) tumors from 40 untreated DLBCL patients participating in a clinical trial (N0489; NCT00301821) was used for immunohistochemistry (IHC) studies of PTPN6. 20 All patients signed informed consent approved by the institutional review board at each participating site in N0489. Tissue microarrays were constructed and included 10 benign tonsil controls from the Predolin Biobank at the Mayo Clinic. For the studies of methylation, DNA from fresh or frozen DLBCL tumor cells was required. As this type of sample was not available from the N0489 trial, we obtained frozen cells from 40 other DLBCL patient samples from the University of Iowa/Mayo Lymphoma SPORE Biospecimen Core. All SPORE patients also provided informed consent for use of their tumor tissue for research. B cells from normal controls were isolated 1 from peripheral blood mononuclear cells (n ¼ 3) using CD19 microbeads (Miltenyi Biotec, Auburn, CA, USA). The DLBCL human cell lines OCILy3 (Ly3), OCILy10 (Ly10) and SUDHL2 (DHL2) used in this study were a kind gift from Dr Louis Staudt (NCI, Bethesda, MD, USA). 4 They were grown in 20% human serum in Iscove's Modified Dulbecco's medium.
Quantitative reverse transcriptase-PCR for PTPN6
Total RNA was extracted from DLBCL patient samples (n ¼ 9) and CD19 normal B cells (n ¼ 3) using RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and cDNAs were synthesized using SuperScript III First-Strand Synthesis SuperMix (Invitrogen, Carlsbad, CA, USA 
IHC for PTPN6 expression
The FFPE slides were deparaffinized and endogenous peroxidase activity was quenched by incubation of sections in a solution of 3% hydrogen peroxide and absolute methanol. Antigen retrieval was performed using citrate at pH 6.1. The slides were placed on a Dako Cytomation autostainer with the PTPN6 antibody (Abcam, Cambridge, MA, USA), DAKO advance detection system, and substrate. The slides were reviewed and scored by the study hematopathologist (AD). The expression of PTPN6 was assessed semi-quantitatively as follows; Neg o10%, 10- 
Methylation analysis by high-resolution melting (HRM)
Methylation standards were mixed to produce 100, 50, 25, 10, 5, and 0% methylation control samples. Amplification primers, 5
0 -gcgTGGGTT AGGGAGGGTTG-3 0 and 5 0 -TTACACACTCCAAACCCAAATAATAC-3 0 , were designed using methprimer (http://www.urogene.org/methprimer/index1.html). PCR reactions were performed using 10 ng bisulfate-modified DNA on an LC480 II using the LC480 High-Resolution Melting Master Kit reagents (Roche, Indianapolis, IN, USA). PCR cycling parameters consisted of an initial denaturation step of 95 1C for 10 min, 20 cycles of touchdown PCR (95 1C for 10 s, 65 1C -0.5 1C/cycle for 15 s, 72 1C for 10 s) and 18 cycles of PCR (95 1C for 10 s, 55 1C for 15 s, 72 1C for 10 s). PCR products were denatured at 95 1C for 1 min and melting profiles generated by cooling samples at 40 1C for 1 min, followed by melting from 65-95 1C at 0.021 per second collecting 25 data points every second. Data were analyzed using the Gene Scanning module of the LC480 analysis software (Roche). Profiles were normalized using a 5 1C window before and after melting. The slope of the melting profile was plotted, and based on control samples, methylated product was shown to melt at 82.5 1C and unmethylated at 80.2 1C. Methylation was estimated by comparing relative peak size at 80.2 1C to that of controls.
Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was performed using the ChIP Assay Kit (EMD Millipore) with antibodies to H3K9me3, H3K27me3, H3K9Ac (Abcam) and IgG as per the manufacturer's instructions. Briefly, 2 million cells were fixed with 1% formaldehyde and cells were then re-suspended in SDS lysis buffer and immunoprecipitated. The resulting complex was pelleted with protein A agarose, and eluted with elution buffer. Histone-DNA crosslinks were reversed in sodium chloride and DNA was recovered by phenol/chloroform extraction. Immunoprecipitated DNA and input samples were analyzed by PCR. The following primers for the PTPN6 gene promoter were used: 5 0 -AG TGCCACCCTGCTCTGCTTC-3 0 (forward) and the 5 0 -CAGTTCTGGGGCTGCCA CT-3 0 (reverse). 5S rRNA gene was used as a control for the ChIP assay. 23 Treatment with DNA methyltransferase and histone deacetylase inhibitors (HDACi) DLBCL cells were seeded at a density of 1 million cells/ml in 25 cm 2 culture flasks; then treated with 5-azacytidine (5-Aza; Sigma-Aldrich, St Louis, MO, USA) or LBH589 (Novartis Pharmaceuticals, Basel, Switzerland) alone or in combination at the indicated concentrations. Fresh media containing 5-Aza and/or LBH589 were added every 2 days for 6 days. Cells were harvested at the time points indicated and used for western blot and survival analysis using flow cytometry with Annexin/Propidium Iodide staining. 24 
RESULTS
PTPN6 is lost or silenced in DLBCL tumors
We analyzed PTPN6 mRNA expression in DLBCL (n ¼ 9) patient specimens and normal B-cells by quantitative reverse transcriptase-PCR. Decreased expression of PTPN6 mRNA was observed in all the DLBCL patient samples as compared with normal B cells (Figure 1a) . To confirm the PTPN6 mRNA expression at the protein level, FFPE DLBCL tumor samples from N0489 clinical trial (n ¼ 40) along with normal tonsils (n ¼ 10) were stained for the detection of PTPN6 protein by IHC. All normal tonsils (10/10) were strongly positive for PTPN6 (480%; þ þ þ ); however, differential expression of PTPN6 staining was found among the DLBCL tumors (Figures 1b and c) . PTPN6 expression was completely lost in 17.5% (7/40) of cases (PTPN6 negative); 7.5% (3/40) of cases had very low expression of PTPN6 (10-30%; þ ); 27.5% (11/40) cases had 30-80% ( þ þ ) of tumor cells staining positive and, 47.5% (19/40) cases had 480% ( þ þ þ ) of cells PTPN6 positive. These data, when taken together, confirm that PTPN6 is strongly expressed in normal B cells and can be lost or suppressed in DLBCL tumors.
CpG1 island are not hypermethylated in PTPN6 promoter 2 Promoter methylation has been found to be an important mechanism regulating PTPN6 expression in peripheral T-cell lymphomas and multiple myeloma. 17, 18, 25 DLBCL patient samples were analyzed for PTPN6 methylation by MSP1/UMSP PCR by use of previously published PCR primers 17 that encompass the CpG1 region of PTPN6 P2 (Figure 2a) . CpG1 hypermethylation by MSP PCR was detected in the tumor cells from only one patient (#18; 1/38; 2.6%; Figure 2b ), which after further review had a neuroendocrine carcinoma (vide infra). None of the DLBCL cell lines (Ly3, DHL2, Ly10) along with CD19 þ B cells tested showed hypermethylation of PTPN6 at CpG1 (data not shown). As the MSP PCR technique yields qualitative rather than quantitative data, it is unable to provide information about the degree of methylation at specific CpG1 sites. In order to quantify methylation, pyrosequencing was performed on the same DLBCL samples and methylation level was generated for CpG1 sites in the PTPN6 promoter 2. 26, 27 Cases with o10% methylation were categorized as unmethylated; cases 410% methylation were low (10-25%), intermediate (25-40%) and high methylation (440%). Table 1 shows the average percent methylation of CpG1 sites in the DLBCL patients and cell lines. The pyrosequencing analysis was consistent with MSP PCR analysis and demonstrated that again only patient sample #18 was highly hypermethylated (76%) at CpG1 (Table 1) . CD19 þ normal B cells were unmethylated (9.4%), whereas the Raji Burkitt lymphoma cell line (positive control for PTPN6 methylation) was highly methylated (86%) at CpG1 (data not shown). 18 To confirm the MSP1 PCR and pyrosequencing results, we performed HRM on the same DLBCL DNA samples. HRM is a very sensitive method for the detection of methylation at gene-specific loci. 28 With HRM, we again found only one sample (patient #18) with high levels of methylation with the peak of the melt profile falling between that of the 50 and 100% methylation controls (Supplementary Figure 1A) . Seven additional samples showed low Figure 1B relative to standards. Our data conclusively demonstrate that PTPN6 methylation at CpG1 is absent in DLBCL tumors. In fact, this finding led us to re-examine the clinical and pathologic data from case #18 that we found methylated. The tumor was originally classified as DLBCL in the clinical record and our biobank; however, the final pathology diagnosis was a neuroendocrine carcinoma.
Novel PTPN6 promoter CpG island sites (CpG2) are hypermethylated in DLBCL tumors The finding that PTPN6 was lost or silenced in many of the clinical samples without finding any CpG1 P2 hypermethylation led us to extend our methylation studies to another CpG island (named CpG2). This CpG2 island is located at the proximal end of the PTPN6 P2 promoter and contains eight CpG sites (Figure 2a) . Hypermethylation of the CpG2 island has not been previously studied for the PTPN6 gene in any hematological malignancy. We designed primers specific for these CpG2 sites and ran the pyrosequencing on the same 37 DLBCL tumors as used above for CpG1 methylation. Using a cutoff of 425% (intermediate to high methylation), 57% (21/37) of patient samples were methylated ( Table 1 ). The Ly3, Ly10 and DHL2 DLBCL cell lines were also hypermethylated at CpG2 (Table 1) . CpG2 pyrosequencing data were confirmed in seven DLBCL samples by methylationspecific PCR using MSP2/UMSP2 primers (Figure 2c) . Sequencing of the methylated MSP products from methylated DNA control and patient #18 and #1 sample showed no change in C to T residues in the CpG1 sites confirming that PTPN6 was indeed hypermethylated in that sample (Figure 2d) . Overall, these data demonstrate that PTPN6 hypermethylation occurs at this novel CpG2 site in the PTPN6 P2 promoter in many DLBCL tumors and may explain the loss or silencing of PTPN6 found in our patient samples.
Re-expression of PTPN6 with 5-Aza, a DNA methyltransferase inhibitor To further confirm the role of DNA methylation in PTPN6 regulation, we investigated PTPN6 re-expression after treatment of Ly3 (high methylation) and DHL2 (intermediate methylation) cells with the DNA methyltransferase inhibitor 5-Aza. 5-Aza treatment increased PTPN6 mRNA expression compared with untreated control in both cell lines (Figure 3a) . Ly3 was more amenable to PTPN6 re-expression compared with DHL2 cells most likely because of the higher basal hypermethylation of CpG2 in Ly3 cells (Table 1) . In Ly3, treatment with 5-Aza led to a progressive demethylation of PTPN6 that started from day 2 onwards, as shown by positive U-MSP with increasing amplification intensity (Figure 3b ). 5-Aza-mediated demethylation of CpG2 in Ly3 was confirmed by pyrosequencing demonstrating inhibition of CpG2 methylation by 59% by day 4 (Figure 3c ). Interestingly, this progressive CpG2 demethylation of PTPN6 was associated with a parallel re-expression of PTPN6 protein beginning from day 2 onwards specifically in Ly3 cells with modest effect in DHL2 cells at days 4 and 6 ( Figure 3d ). This resulted in a corresponding downregulation of activated STAT3 in a similar time-dependent manner (Figure 3e ). To investigate the influence of ectopic PTPN6 wild-type (WT) and mutant expression on STAT3 activation, we transiently overexpressed vector alone and WT PTPN6 plasmids in the HEK-293 cells. Figure 3f clearly demonstrates overexpression of the PTPN6 in WT PTPN6-transfected cells as compared with vector alone. Interestingly, overexpression of WT PTPN6 was able to completely dephosphorylate STAT3 in these cells (Figure 3f ). Treatment of Ly3 and DHL2 cells with 5-Aza (3 mM) for 0-6 days significantly (P ¼ 0.0008 for Ly3 and P ¼ 0.03 for DHL2) reduced the cell survival at day 6 ( Figure 3g ). Overall, these data suggest that the DNA methyltransferase inhibitor 5-Aza was able to successfully demethylate PTPN6 promoter 2 is associated with inactivating histone marks To further investigate epigenetic control of PTPN6 in DLBCL, we proceeded to study whether histone modifications (methylation and acetylation) of the PTPN6 P2 were involved in the regulation of PTPN6 expression. For the studies of histone methylation, ChIP assays were performed in the Ly3 cell line, normal CD19 þ cells and in Raji cells by using antibodies to repressing marks on histones. In Ly3 cells, we found the PTPN6 P2 core region to be enriched with trimethylation of lysine 9 on histone H3 (H3K9me3) and lysine 27 on histone H3 (H3K27me3) as compared with CD19 þ cells (Figures 5a and b) . To confirm that these suppressive histone marks regulate PTPN6 expression, we treated Ly3 cells with the histone methyltransferase inhibitor 3-deazaneplanocin A (DZNep, Sigma-Aldrich). DZNep is an EZH2 histone methyltransferase inhibitor that selectively inhibits the H3K27 trimethylation mark. 30 Treatment with DZNep increased the PTPN6 expression in Ly3 cells (Figure 5c) . Results of the ChIP assay showed reduced expression of the H3K27me3 histone mark in the DZNep-treated cells within the PTPN6 P2 (Figure 5d ). To evaluate the role of histone acetylation, we performed the ChIP assay with LBH treatment and demonstrated increased acetylation at lysine 9 on histone H3 (H3K9Ac; Figure 5e ) in PTPN6 P2 without any effect on the H3K27me3 mark (data not shown). Moreover, LBH treatment resulted in increased expression of PTPN6 mRNA (Figure 5f ).
DISCUSSION
We have shown in this study that expression of an important protein tyrosine phosphatase, PTPN6, is suppressed or lost in the 53% of DLBCL tumors as compared with normal B cells. The PTPN6 gene has been shown to be silenced in T-cell lymphomas of various types [31] [32] [33] but PTPN6 protein expression in the most common lymphoma, DLBCL, has not been reported. Others have shown PTPN6 to be silenced in other unusual types of lymphoma such as adult T-cell leukemia/lymphoma and NK/T-cell lymphomas as well as in acute and chronic leukemias. 17, 25 Several studies in hematological malignancies have shown that promoter hypermethylation of the PTPN6 gene occurs at the known CpG1 site on promoter 2. 18, 25 In DLBCL, however, we demonstrated that PTPN6 is not methylated at CpG1 sites. These results appear to be conclusive as we performed the experiments on the same samples by three different methods (MSP1/UMSP1 PCR, HRM and pyrosequencing) in three different independent laboratories at our institution and found the same results. These results in DLBCL are in contrast with previous reports describing PTPN6 P2 CpG1 methylation to be present in DLBCL. 34 The possible explanation for these discordant results could be the differences in the methylation techniques used, differences in DNA sample source used (frozen vs FFPE) or even geographical differences between DLBCL patient samples (United States vs Africa). In order to gain further mechanistic insight to PTPN6 suppression, we further analyzed the PTPN6 promoter 2 and observed a novel CpG2 island at the proximal end. Pyrosequencing for CpG2 sites on the same 37 DLBCL samples used for CpG1 studies found 57% of cases with CpG2 hypermethylation. To our knowledge, this is the first description of methylation at this CpG island on PTPN6 P2. Histone modification also has an important role in gene silencing by methylating inactivating histone marks. We performed the ChIP assay in DLBCL cell lines and demonstrated that PTPN6 P2 was enriched for the silencing histone marks H3K9me3 and H3K27me3 in DLBCL cell lines but not in normal B cells. These findings support the notion that control of PTPN6 P2 in DLBCL tumors is associated with both DNA promoter methylation (CpG2) and histone methylation/acetylation.
In conclusion, these data provide a comprehensive characterization of the epigenetic mechanisms leading to PTPN6 deregulation in the DLBCL tumors. These findings support the notion that control of PTPN6 P2 in DLBCL tumors is associated with DNA methylation, histone methylation and histone acetylation. These findings explain why treatment with 5-Aza, DZNep and LBH589 can reactivate PTPN6 expression and function. PTPN6 expression and patterns of methylation and acetylation may prove useful as diagnostic and prognostic markers and provide a rationale to test epigenetic therapy in DLBCL patients. 
